Urine concentrations changes of cysteinyl leukotrienes in non-obese children with obstructive sleep apnea undergoing adenotonsillectomy

Mousailidis, George K.; Lachanas, Vassilios A.; Vasdeki, Afroditi; Alexopoulos, Emmanouel Ι.; Kaditis, Athanasios G.; Petinaki, Efthymia; Balatsos, Nikolaos A. A.; Bizakis, John G.; Skoulakis, Charalampos

doi:10.1016/j.ijporl.2018.10.002

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior research has shown that collecting physiological data via polysomnography can lead to wearer discomfort during sleep [53][54][55]. In light of this, our study introduces an algorithmic analysis module tailored for the interpretation of physiological data harnessed from intelligent wearable devices.…”

Section: Discussionmentioning

confidence: 99%

Integrating Mobile Devices and Wearable Technology for Optimal Sleep Conditions

Wang,

Chen

2023

Applied Sciences

View full text Add to dashboard Cite

As medical technology continues to evolve, the importance of real-time feedback from physiological signals is increasingly being recognized. The advent of the Internet of Things (IoT) has facilitated seamless connectivity between sensors and virtual networks, enabling the integration of thoughtful medical care with real-time feedback capabilities. This project uses cloud storage technology and cloud software algorithms to enable data sharing and real-time feedback. Its main focus is to provide a system for real-time feedback on physiological signals and sleep quality analysis. The system uses smart wristbands and smart mobile devices to collect, transmit, and analyze physiological data. During sleep, users wear these devices, which capture and analyze their physiological data. The analyzed data are then stored in a cloud-based database. The research involves studying sleep quality and determining optimal sleep quality parameters based on the data stored in the cloud database. These parameters are designed to improve sleep quality. They are then transmitted to a mobile sleep aid device to control light conditions. The sleep aid software used in previous generations of mobile devices is the basis for expanding the integration of the sleep detection system. By combining the software of a mobile device platform with that of a smart wearable device, data can be obtained to monitor the wearer’s movements, such as turning over and heartbeat. The monitoring aspect includes tracking the turning time, distance, and speed, while the heartbeat monitoring includes detecting changes in heart rate, frequency, and interval using photoplethysmography (PPG) and smart wearable devices. Subsequently, artificial intelligence methods are employed to conduct statistical analysis and categorize the gathered extensive dataset. The system reads the data and provides the user with assessments and suggestions to improve sleep quality and overall sleep condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Integrating Mobile Devices and Wearable Technology for Optimal Sleep Conditions

Wang,

Chen

2023

Applied Sciences

View full text Add to dashboard Cite

show abstract

“…Goldbart observed high levels of cysteinyl leukotriene (CysLTs) and high expression of CysLTs receptor in adenoids and tonsil tissues of children with OSA in 2005 (Goldbart et al, 2005). In the past few years, researchers have also repeatedly demonstrated that cyslt-mediated allergic reactions are associated with abnormal hyperplasia of adenoidal and tonsillar hypertrophy in children with OSA (Tsaoussoglou et al, 2014;Feng et al, 2015;Mousailidis et al, 2018). Montelukast is a typical leukotriene receptor antagonist, which is commonly used to control inflammatory response (Nachalon et al, 2014).…”

Section: Figurementioning

confidence: 99%

Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope

Wang,

Wu,

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Adenoidal hypertrophy (AH) is one of the most common causes of upper airway obstruction in children. Drug and surgical treatment are the typical treatment of AH. The study on the inflammatory mechanism of AH in children provides a new idea for preoperative intervention and non-surgical treatment with anti-inflammatory drugs such as montelukast sodium (a cysteine leukotriene receptor antagonist). The aim of this study is to evaluate the effect of montelukast sodium on adenoidal lymphoid tissue pathology in children with AH under light microscope.Objective: To study whether there is any change in pathology of the adenoidal lymphoid tissue under the light microscope compared with the control group in children with moderate to severe simple AH treated with montelukast sodium for 1 month before operation.Materials and methods: Twenty patients (8 males, 12 females, 3–8 years old) with moderate to severe AH who were prepared for surgical treatment were selected. All the patients were examined by Nasopharyngeal CT and hemocyte analysis before operation. 20 subjects were randomly divided into two groups: One group was given montelukast chewable tablets 5 mg/d, qn, for 4 weeks; The control group was given placebo 5 mg/d, qn, for 4 weeks. After 4 weeks, the adenoids were removed and examined histopathology.Results: Compared with the control group, the number of lymphocytes in the blood cell analysis of the study group was significantly reduced, with a statistically significant difference (p < 0.05). And the number of germinal centers in adenoid tissue of the study group was relatively reduced, no small cyst was found in the epithelium, and the degree of inflammatory cell infiltration was reduced, with a statistically significant difference (p < 0.05).Conclusion: Montelukast can reduce the number of reactive cells, the number of lymphocytes in blood cells and blood vessels in adenoid lymphoid tissue, which can provide a new idea for preoperative intervention and non-surgical treatment of adenoid hypertrophy in children. However, this is only a pilot study and a longer treatment period is needed to assess the long-term effects of montelukast sodium on adenoid lymphoid tissue.Clinical Trial Registration: www.Chictr.org.cn, identifier ChiCTR2300075040.

show abstract